These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 19959941

  • 1. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
    Shafa S, Borum ML, Igiehon E.
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):122-3. PubMed ID: 19959941
    [No Abstract] [Full Text] [Related]

  • 2. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED, Alpat SN, Ozgunes I, Usluer G.
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [Abstract] [Full Text] [Related]

  • 3. Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege.
    Ito T, Suzuki T, Funakoshi A, Tokura Y.
    Eur J Dermatol; 2014 Sep; 24(5):631-3. PubMed ID: 25115439
    [No Abstract] [Full Text] [Related]

  • 4. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N, Aykin N, Demirdal T, Cevik F.
    Eur J Dermatol; 2006 Sep; 16(5):579-80. PubMed ID: 17101483
    [No Abstract] [Full Text] [Related]

  • 5. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin.
    Patrk I, Morović M, Markulin A, Patrk J.
    Dermatology; 2014 Sep; 228(1):42-6. PubMed ID: 24434490
    [Abstract] [Full Text] [Related]

  • 6. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
    Lübbe J, Kerl K, Negro F, Saurat JH.
    Br J Dermatol; 2005 Nov; 153(5):1088-90. PubMed ID: 16225644
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.
    Keeffe EB, Kowdley KV.
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S1-2. PubMed ID: 15597022
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cutaneous reactions to interferon and ribavirin.
    Chamberlain AJ, Poon E.
    Intern Med J; 2004 Aug; 34(8):519. PubMed ID: 15317557
    [No Abstract] [Full Text] [Related]

  • 13. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
    Musialik J, Petelenz M, Błoñska-Fajfrowska B, Hartleb M.
    Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303
    [No Abstract] [Full Text] [Related]

  • 14. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ, Romagosa R, Vincek V.
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract] [Full Text] [Related]

  • 15. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
    Choy-Shan A, Berezovskaya S, Zinn A, Sedlis SP, Bini EJ.
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1438-40. PubMed ID: 19907230
    [No Abstract] [Full Text] [Related]

  • 16. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M, Pérez Carreras M, Muñoz Gómez R, Castellano Tortajada G.
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract] [Full Text] [Related]

  • 17. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Virolés Torrent S, López Nuñez C, Hombrados Verde M, Figa Francesch M, Ferri Iglesias MJ, Louvriex Freire R, Acero Fernández D.
    Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
    [No Abstract] [Full Text] [Related]

  • 18. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.
    Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oliva N.
    Br J Dermatol; 2004 May; 150(5):1046-7; author reply 1047. PubMed ID: 15149535
    [No Abstract] [Full Text] [Related]

  • 19. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
    Tavakoli-Tabasi S, Bagree A.
    J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
    [Abstract] [Full Text] [Related]

  • 20. Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection.
    Conde-Taboada A, de la Torre C, Feal C, Mayo E, Gonzalez-Sixto B, Cruces MJ.
    Br J Dermatol; 2005 Nov; 153(5):1070-2. PubMed ID: 16225630
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.